Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells

Mathew G. Angelos, Paige N. Ruh, Beau R. Webber, Robert H. Blum, Caitlin D. Ryan, Laura Bendzick, Seonhui Shim, Ashley M. Yingst, Dejene M. Tufa, Michael R. Verneris, Dan S. Kaufman

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


The aryl hydrocarbon receptor (AHR) plays an important physiological role in hematopoiesis. AHR is highly expressed in hematopoietic stem and progenitor cells (HSPCs) and inhibition of AHR results in a marked expansion of human umbilical cord blood-derived HSPCs following cytokine stimulation. It is unknown whether AHR also contributes earlier in human hematopoietic development. To model hematopoiesis, human embryonic stem cells (hESCs) were allowed to differentiate in defined conditions in the presence of the AHR antagonist StemReginin-1 (SR-1) or the AHR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). We demonstrate a significant increase in CD34+CD31+ hematoendothelial cells in SR-1-treated hESCs, as well as a twofold expansion of CD34+CD45+ hematopoietic progenitor cells. Hematopoietic progenitor cells were also significantly increased by SR-1 as quantified by standard hematopoietic colony-forming assays. Using a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-engineered hESC-RUNX1ctdTomato reporter cell line with AHR deletion, we further demonstrate a marked enhancement of hematopoietic differentiation relative to wild-type hESCs. We also evaluated whether AHR antagonism could promote innate lymphoid cell differentiation from hESCs. SR-1 increased conventional natural killer (cNK) cell differentiation, whereas TCDD treatment blocked cNK development and supported group 3 innate lymphoid cell (ILC3) differentiation. Collectively, these results demonstrate that AHR regulates early human hematolymphoid cell development and may be targeted to enhance production of specific cell populations derived from human pluripotent stem cells.

Original languageEnglish (US)
Pages (from-to)3428-3439
Number of pages12
Issue number26
StatePublished - Jun 29 2017

Bibliographical note

Funding Information:
This work was supported in part by the following National Institutes of Health grants: National Cancer Institute R01CA203348 (D.S.K.), National Institute of Diabetes and Digestive and Kidney Diseases F30DK107071 (M.G.A.), National Institute of Allergy and Immunology R01AI100879 (M.R.V.), and National Institute of General Medicine Sciences T32GM113846 (M.G.A. and D.S.K.) and T32GM008244 (M.G.A.). Other support was received from the Regenerative Medicine Minnesota program (D.S.K.).

Publisher Copyright:
© 2017 by The American Society of Hematology.


Dive into the research topics of 'Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells'. Together they form a unique fingerprint.

Cite this